Exploration of risk factors for VTE
| Risk factor . | Association with risk of VTE, SHR (95% CI) . |
|---|---|
| History of VTE | 3.69 (2.00-6.81), P < .001 |
| Stage of disease (stage IV vs I-III) | 1.71 (0.62-4.73), P = .303 |
| ECOG performance status (≥1 vs 0) | 0.92 (0.43-1.95), P = .828 |
| Charlson comorbidity index (per point increase) | 1.05 (0.94-1.17), P = .366 |
| Grade | 0.55 (0.27-1.15), P = .112 |
| Sex (male vs female) | 1.48 (0.79-2.76), P = .221 |
| Age (per 10-y increase) | 1.04 (0.87-1.23), P = .684 |
| BMI (per point increase) | 1.04 (0.99-1.09), P = .066 |
| Occurrence of immune-related adverse event | 0.78 (0.41-1.49), P = .457 |
| Khorana score (per 1-point increase) | 0.93 (0.60-1.46), P = .761 |
| Khorana score (≥2 vs 0-1) | 0.69 (0.32-1.51), P = .353 |
| PD-L1 TPS (per 10% increase) | 1.10 (0.97-1.26), P = .147 |
| Anticoagulation at baseline | 1.11 (0.52-2.36) P = .793 |
| Antiplatelet therapy at baseline | 1.17 (0.58-2.35), P = .654 |
| Risk factor . | Association with risk of VTE, SHR (95% CI) . |
|---|---|
| History of VTE | 3.69 (2.00-6.81), P < .001 |
| Stage of disease (stage IV vs I-III) | 1.71 (0.62-4.73), P = .303 |
| ECOG performance status (≥1 vs 0) | 0.92 (0.43-1.95), P = .828 |
| Charlson comorbidity index (per point increase) | 1.05 (0.94-1.17), P = .366 |
| Grade | 0.55 (0.27-1.15), P = .112 |
| Sex (male vs female) | 1.48 (0.79-2.76), P = .221 |
| Age (per 10-y increase) | 1.04 (0.87-1.23), P = .684 |
| BMI (per point increase) | 1.04 (0.99-1.09), P = .066 |
| Occurrence of immune-related adverse event | 0.78 (0.41-1.49), P = .457 |
| Khorana score (per 1-point increase) | 0.93 (0.60-1.46), P = .761 |
| Khorana score (≥2 vs 0-1) | 0.69 (0.32-1.51), P = .353 |
| PD-L1 TPS (per 10% increase) | 1.10 (0.97-1.26), P = .147 |
| Anticoagulation at baseline | 1.11 (0.52-2.36) P = .793 |
| Antiplatelet therapy at baseline | 1.17 (0.58-2.35), P = .654 |